{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:51:37Z","timestamp":1790106697512,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ymthe.2022.05.023","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:28:04Z","timestamp":1653524884000},"page":"2429-2442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene"],"prefix":"10.1016","volume":"30","author":[{"given":"Nathalie","family":"Majeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Fortin-Archambault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouir\u00e9","family":"Yam\u00e9ogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-9195","authenticated-orcid":false,"given":"Jacques P.","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.05.023_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2022.05.023_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in\u00a0vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib4","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2022.05.023_bib5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ymthe.2019.01.019","article-title":"Micro-dystrophin genes bring hope of an effective therapy for Duchenne muscular dystrophy","volume":"27","author":"Davies","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ymthe.2019.01.002","article-title":"Development of novel micro-dystrophins with enhanced functionality","volume":"27","author":"Ramos","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib7","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.2018.012","article-title":"Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients","volume":"29","author":"Duan","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib9","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-022-01197-9","article-title":"CRISPR-Cas9 gene therapy for Duchenne muscular dystrophy","author":"Happi Mbakam","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2022.05.023_bib10","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41467-020-14957-y","article-title":"Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping","volume":"11","author":"Gee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.05.023_bib11","doi-asserted-by":"crossref","first-page":"eaan8081","DOI":"10.1126\/scitranslmed.aan8081","article-title":"Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy","volume":"9","author":"Amoasii","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.05.023_bib12","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1038\/mtna.2015.58","article-title":"Efficient restoration of the dystrophin gene reading frame and protein structure in DMD myoblasts using the CinDel method","volume":"5","author":"Iyombe-Engembe","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2022.05.023_bib13","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ymthe.2018.08.010","article-title":"CRISPR-induced deletion with SaCas9 restores dystrophin expression in dystrophic models in\u00a0vitro and in\u00a0vivo","volume":"26","author":"Duchene","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In\u00a0vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.05.023_bib15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In\u00a0vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2022.05.023_bib16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/mt.2015.192","article-title":"CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice","volume":"24","author":"Xu","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in\u00a0vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2022.05.023_bib18","doi-asserted-by":"crossref","first-page":"eabg4910","DOI":"10.1126\/sciadv.abg4910","article-title":"Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing","volume":"7","author":"Chemello","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2022.05.023_bib19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/d41573-021-00164-x","article-title":"Gene therapy community grapples with toxicity issues, as pipeline matures","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.05.023_bib20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib21","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.2021010864","article-title":"The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective","volume":"138","author":"Bolous","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2022.05.023_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","article-title":"Extracellular vesicles as drug delivery systems: why and how?","volume":"159","author":"Elsharkasy","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2022.05.023_bib23","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1080\/21655979.2022.2030571","article-title":"A peptide derived from the N-terminus of charged multivesicular body protein 6 (CHMP6) promotes the secretion of gene editing proteins via small extracellular vesicle production","volume":"13","author":"Fan","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.ymthe.2022.05.023_bib24","doi-asserted-by":"crossref","first-page":"e12076","DOI":"10.1002\/jev2.12076","article-title":"Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing","volume":"10","author":"Yao","year":"2021","journal-title":"J.\u00a0Extracell. Vesicles"},{"key":"10.1016\/j.ymthe.2022.05.023_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1021\/acs.nanolett.8b02689","article-title":"In\u00a0vitro and in\u00a0vivo RNA inhibition by CD9-HuR functionalized exosomes encapsulated with miRNA or CRISPR\/dCas9","volume":"19","author":"Li","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2022.05.023_bib26","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.ymthe.2021.01.020","article-title":"A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties","volume":"29","author":"Dooley","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib27","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.3390\/ijms22116072","article-title":"CRISPR\/Cas9: principle, applications, and delivery through extracellular vesicles","volume":"22","author":"Horodecka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2022.05.023_bib28","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.1093\/nar\/gkaa683","article-title":"Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR\/Cas9 system for gene therapy","volume":"48","author":"Zhuang","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2022.05.023_bib29","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.ymthe.2020.12.018","article-title":"Exosome-mediated improvement in membrane integrity and muscle function in dystrophic mice","volume":"29","author":"Leng","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib30","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1038\/s41598-021-86910-y","article-title":"Immunomagnetic sequential ultrafiltration (iSUF) platform for enrichment and purification of extracellular vesicles from biofluids","volume":"11","author":"Zhang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.05.023_bib31","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1007\/s00018-019-03071-y","article-title":"Extracellular vesicle isolation methods: rising impact of size-exclusion chromatography","volume":"76","author":"Monguio-Tortajada","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.ymthe.2022.05.023_bib32","doi-asserted-by":"crossref","first-page":"35928","DOI":"10.1038\/srep35928","article-title":"Revealing the diversity of extracellular vesicles using high-dimensional flow cytometry analyses","volume":"6","author":"Marcoux","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.05.023_bib33","doi-asserted-by":"crossref","first-page":"593750","DOI":"10.3389\/fcell.2020.593750","article-title":"Employing flow cytometry to extracellular vesicles sample microvolume analysis and quality control","volume":"8","author":"Maia","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2022.05.023_bib34","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41598-017-01731-2","article-title":"Labeling extracellular vesicles for nanoscale flow cytometry","volume":"7","author":"Morales-Kastresana","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.05.023_bib35","doi-asserted-by":"crossref","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Th\u00e9ry","year":"2018","journal-title":"J.\u00a0Extracell. Vesicles"},{"key":"10.1016\/j.ymthe.2022.05.023_bib36","doi-asserted-by":"crossref","first-page":"7645","DOI":"10.3390\/s21227645","article-title":"Advances in biosensors technology for detection and characterization of extracellular vesicles","volume":"21","author":"Bari","year":"2021","journal-title":"Sensors"},{"key":"10.1016\/j.ymthe.2022.05.023_bib37","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCRESAHA.117.311767","article-title":"What are we looking at? extracellular vesicles, lipoproteins, or both?","volume":"121","author":"Simonsen","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2022.05.023_bib38","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/s41598-020-57497-7","article-title":"A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum","volume":"10","author":"Brennan","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.05.023_bib39","doi-asserted-by":"crossref","first-page":"1560809","DOI":"10.1080\/20013078.2018.1560809","article-title":"Comparison of small extracellular vesicles isolated from plasma by ultracentrifugation or size-exclusion chromatography: yield, purity and functional potential","volume":"8","author":"Takov","year":"2018","journal-title":"J.\u00a0Extracell. Vesicles"},{"key":"10.1016\/j.ymthe.2022.05.023_bib40","doi-asserted-by":"crossref","first-page":"22519","DOI":"10.1038\/srep22519","article-title":"Cells release subpopulations of exosomes with distinct molecular and biological properties","volume":"6","author":"Willms","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2022.05.023_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nn.2467","article-title":"A robust and high-throughput Cre reporting and characterization system for the whole mouse brain","volume":"13","author":"Madisen","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2022.05.023_bib42","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1074\/jbc.M709410200","article-title":"Generation and characterization of transgenic mice with the full-length human DMD gene","volume":"283","author":"t Hoen","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2022.05.023_bib43","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/j.ymthe.2021.04.002","article-title":"CRISPR technologies for the treatment of Duchenne muscular dystrophy","volume":"29","author":"Choi","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib44","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nbt.4148","article-title":"Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy","volume":"36","author":"Ryu","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.05.023_bib45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in\u00a0vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2022.05.023_bib46","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving forward after two deaths in a gene therapy trial of myotubular myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib47","doi-asserted-by":"crossref","first-page":"120826","DOI":"10.1016\/j.biomaterials.2021.120826","article-title":"Microfluidic formulation of nanoparticles for biomedical applications","volume":"274","author":"Shepherd","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.ymthe.2022.05.023_bib48","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1021\/acs.chemrestox.0c00051","article-title":"Nanomaterials and innate immunity: a perspective of the current status in nanosafety","volume":"33","author":"Cronin","year":"2020","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ymthe.2022.05.023_bib49","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1021\/acs.nanolett.1c00094","article-title":"Natural or synthetic RNA delivery: a stoichiometric comparison of extracellular vesicles and synthetic nanoparticles","volume":"21","author":"Murphy","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2022.05.023_bib50","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","article-title":"Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges","volume":"6","author":"Ha","year":"2016","journal-title":"Acta Pharm. Sin B"},{"key":"10.1016\/j.ymthe.2022.05.023_bib51","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.3390\/ijms21124407","article-title":"Transport of extracellular vesicles across the blood-brain barrier: brain pharmacokinetics and effects of inflammation","volume":"21","author":"Banks","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2022.05.023_bib52","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of adeno-associated virus (AAV) and recombinant AAV vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.ymthe.2022.05.023_bib53","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41551-019-0431-2","article-title":"Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy","volume":"3","author":"Moreno","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2022.05.023_bib54","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/s41467-021-26830-7","article-title":"Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models","volume":"12","author":"Hakim","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.05.023_bib55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.05.023_bib56","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/jcp.30064","article-title":"CRISPR\/Cas gene therapy","volume":"236","author":"Zhang","year":"2021","journal-title":"J.\u00a0Cell Physiol"},{"key":"10.1016\/j.ymthe.2022.05.023_bib57","doi-asserted-by":"crossref","first-page":"7362","DOI":"10.3390\/ijms21197362","article-title":"Gene editing by extracellular vesicles","volume":"21","author":"Kostyushev","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2022.05.023_bib58","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/pr9020356","article-title":"Overview and update on methods for cargo loading into extracellular vesicles","volume":"9","author":"Han","year":"2021","journal-title":"Processes"},{"key":"10.1016\/j.ymthe.2022.05.023_bib59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12943-019-0965-7","article-title":"Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance","volume":"18","author":"Maacha","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2022.05.023_bib60","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.3390\/ijms21124463","article-title":"Extracellular vesicles in cancer metastasis: potential as therapeutic targets and materials","volume":"21","author":"Kogure","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2022.05.023_bib61","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccell.2016.10.009","article-title":"Extracellular vesicles in cancer: cell-to-cell mediators of metastasis","volume":"30","author":"Becker","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2022.05.023_bib62","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/biom10060839","article-title":"Recent advances in CRISPR\/Cas9 delivery strategies","volume":"10","author":"Yip","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2022.05.023_bib63","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/14712598.2020.1787981","article-title":"A tool with many applications: vesicular stomatitis virus in research and medicine","volume":"20","author":"Munis","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2022.05.023_bib64","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10529-016-2064-9","article-title":"Improved delivery of Cas9 protein\/gRNA complexes using lipofectamine CRISPRMAX","volume":"38","author":"Yu","year":"2016","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.ymthe.2022.05.023_bib65","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/thno.47007","article-title":"Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2022.05.023_bib66","doi-asserted-by":"crossref","first-page":"26316","DOI":"10.3402\/jev.v4.26316","article-title":"Extracellular vesicle in\u00a0vivo biodistribution is determined by cell source, route of administration and targeting","volume":"4","author":"Wiklander","year":"2015","journal-title":"J.\u00a0Extracell. Vesicles"},{"key":"10.1016\/j.ymthe.2022.05.023_bib67","doi-asserted-by":"crossref","first-page":"e12085","DOI":"10.1002\/jev2.12085","article-title":"Biodistribution of extracellular vesicles following administration into animals: a systematic review","volume":"10","author":"Kang","year":"2021","journal-title":"J.\u00a0Extracell. Vesicles"},{"key":"10.1016\/j.ymthe.2022.05.023_bib68","doi-asserted-by":"crossref","first-page":"e0193289","DOI":"10.1371\/journal.pone.0193289","article-title":"A dystrophic Duchenne mouse model for testing human antisense oligonucleotides","volume":"13","author":"Veltrop","year":"2018","journal-title":"PLoS One"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622003215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622003215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:28:44Z","timestamp":1783020524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622003215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1525001622003215"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.023","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}